Jade Biosciences, Inc.
NASDAQ:JBIOBiotechnology
-$0.21 today
- Market cap
- $1.07B
- Beta
- 1.45
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$2.24
Volume 0.79M
Average 0.83M
JBIO Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Jade Biosciences, Inc.NASDAQ: JBIO
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q1 FY2026 operating expenses of $43.44M rose 1183.9% year over year, ahead of the +162.6% change in trailing-twelve-month operating expenses. Sequentially, it rose 24.2% from the prior quarter. Over 3 fiscal years it compounded at +28.8% a year.
Context
- Operating expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1183.9% holds above the trailing-twelve-month pace of +162.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 113.54M USD
- Year-over-year change
- +52.8%
- 4-year CAGR
- +49.0%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 113.54M | +52.8% |
| FY2024 | 2024-12-31 | 74.31M | -8.6% |
| FY2023 | 2023-12-31 | 81.31M | +52.9% |
| FY2022 | 2022-12-31 | 53.17M | +131.1% |
| FY2021 | 2021-12-31 | 23.01M | — |
Operating Expenses vs competitors
How JBIO compares with its peers on the latest reported figures
- JBIO's LTM Mar 2026 operating expenses of $133.59M is the 4th highest of the 9 companies compared; the peer median is $86.67M.
- Its year-over-year change of +162.6% is the 2nd highest of 9, against a peer median of +46.1%.
- Over three fiscal years its annual growth of +28.8% compares with a peer median of +44.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $415.76M | +76.1% | +50.9% | — | |
| LTM Mar 2026 | $265.04M | +55.2% | +55.0% | — | |
| LTM Mar 2026 | $162.92M | +24.9% | +67.1% | — | |
| LTM Mar 2026 | $133.59M | +162.6% | +28.8% | — | |
| LTM Mar 2026 | $86.87M | -40.0% | -8.6% | 1038.2% | |
| LTM Mar 2026 | $86.47M | +11.3% | -2.0% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $66.77M | +256.3% | +44.2% | — |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $39.39M | +37.0% | — | — |
| LTM Mar 2026 | $28.61M | +86.5% | +31.4% | — | |
| Peer median (excluding JBIO) | $86.67M | +46.1% | +44.2% | 1038.2% | |
Competitors are the stored peer set for JBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 15K | 68K | 96K | 282K | 0 |
| Gross Profit | (15K) | (68K) | (96K) | (282K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 14.99M | 38.62M | 64.22M | 53.19M | 93.12M |
| Selling, General & Admin | 8.02M | 14.55M | 17.09M | 21.13M | 20.42M |
| Operating Expenses | 23.01M | 53.17M | 81.31M | 74.31M | 113.54M |
| Depreciation & Amortization | 15K | 68K | 96K | 282K | 26K |
| EBITDA | (22.95M) | (51.42M) | (75.37M) | (69.29M) | (127.33M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (23.02M) | (53.24M) | (81.41M) | (74.6M) | (113.54M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 65K | 1.83M | 5.95M | 5.04M | 7.78M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 62K | 1.75M | 5.94M | 5.02M | (13.81M) |
| Income Before Tax | (22.96M) | (51.49M) | (75.47M) | (69.57M) | (127.35M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 3K | 25K | 56K | 55K | 58K |
| Net Income | (22.96M) | (51.51M) | (75.52M) | (69.63M) | (127.41M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (32.96) | (73.67) | (100.38) | (85.26) | (4.06) |
| EPS (Diluted) | (32.96) | (73.67) | (100.38) | (85.26) | (4.06) |
| Weighted Avg Shares | 697.44K | 699.2K | 752.33K | 816.63K | 31.36M |
| Weighted Avg Shares (Diluted) | 697.44K | 699.2K | 752.33K | 816.63K | 31.36M |
Jade Biosciences, Inc.
NASDAQ:JBIO
Intrinsic Alpha fair value
Locked
Current Price
$15.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.